Application of Gypensapogenin B in medicament for treating yellow fever virus infection
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A yellow fever virus and drug technology, applied in the field of biomedicine, to achieve the effect of huge social benefits and research value
Active Publication Date: 2013-01-23
如东文园投资开发有限公司
View PDF0 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
So far, there have been no cases reported in China, but this does not make us relax our vigilance against the virus, because China's climate and geographical environment are complex, and there are many
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0036] Embodiment 1: the preparation of the compound Gypensapogenin B tablet involved in the present invention:
[0037] Take 20 grams of compound Gypensapogenin B, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press machine.
Embodiment 2
[0038] Embodiment 2: the preparation of the compound Gypensapogenin B capsules involved in the present invention:
[0039] Take 20 grams of compound Gypensapogenin B, add conventional auxiliary materials such as starch 180 grams for the preparation of capsules, mix well, and pack into capsules to make 1000 tablets.
[0040] The following pharmacodynamic experiments will further illustrate its drug activity.
experiment example 1
[0042] A kind of application of Gypensapogenin B in the preparation treatment or prevention yellow fever virus infection medicine, its steps are:
[0043] A. Toxicity test of Gypensapogenin B on Vero cells
[0044] Vero cells (African green monkey kidney cells) are susceptible cells to YFV.
[0045] The experimental steps are as follows:
[0046] 1: Inoculate Vero cells: Use DMEM medium containing 10% (v / v) fetal bovine serum to make a single cell suspension, inoculate 1000-10000 cells per well into a 96-well cell culture plate, and inoculate a volume of 100ul per well ;
[0047] 2: Culture Vero cells: at 37°C, 5% (v / v) CO 2 Under culture conditions, cultivate for 2 days;
[0048] 3: Add Gypensapogenin B: Discard the DMEM medium in each well, add 100ul to each well and dilute to the corresponding concentration (0uM, 0.4uM, 1.2 uM, 3.7uM, 11uM, 33uM, 100uM, 300uM) Gypensapogenin B, add 100ul of DMEM medium without 10% (v / v) fetal bovine serum to the control well;
[0049]...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an application of Gypensapogenin B in the preparation of a medicament for treating or preventing yellow fever virus infection. Gypensapogenin B is capable of efficiently inhibiting the propagation of yellow fever virus, but has little toxicity for cells; and Gypensapogenin B is further capable of developing the medicament for treating diseases caused by these viruses, and has wide application prospect. The application of Gypensapogenin B in the preparation of the medicament for treating yellow fever virus infection is firstly disclosed; since the skeleton type belongs to an entirely new skeleton type and the inhibition for yellow fever virus activity is previously unimagined high without any possibility of giving out revelation by other compounds, the application has outstanding substantial characteristics; and simultaneously, the application for preventing and treating yellow fever virus infection is obviously advanced.
Description
technical field [0001] The invention belongs to the field of biomedicine, and more specifically relates to the application of Gypensapogenin B in the preparation of medicines for treating or preventing yellow fever virus infection. Background technique [0002] Yellow fever virus (YFV) is a member of the Flavivirus genus in the family Flaviviridae. Yellow fever virus causes yellow fever, an acute infectious disease. Yellow fever has been designated as a quarantine infectious disease internationally, and China has also designated it as a Class A infectious disease. In 1648, an epidemic of yellow fever was first confirmed in the weekly YUCATAN peninsula. From the 17th to the 19th century, the disease was brought to Europe and North America through transportation. In almost two centuries, yellow fever became one of the most serious plagues in some parts of the United States, Africa, and Europe, causing a large number of deaths. Since the 20th century, the disease has not occ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more